Liquid biopsy for ALK-positive early non-small-cell lung cancer predicts disease relapse.
Future Oncol
; 17(1): 81-90, 2021 Jan.
Article
en En
| MEDLINE
| ID: mdl-32988235
ABSTRACT
Background:
We aimed to determine whether circulating tumor cells (CTCs) and cell-free DNA (cfDNA) aids in prognosis of relapse-free survival (RFS).Methods:
Non-small cell lung cancer patients with ALK mutations were recruited prospectively. CTCs and cfDNA were quantified at different time points. RFS was estimated and correlated.Results:
Baseline median CTCs and cfDNA were 16 cells and 57 ng/mL and declined to nine cells and 30 ng/mL, respectively, postsurgery in 150 patients. Interestingly, patients without detectable CTCs postsurgery fared better for RFS. cfDNA monitoring showed deviations within 7 months of surgery that were significant predictors for RFS.Conclusion:
Short-term monitoring of CTCs and cfDNA variations shows promise for early risk detection and may aid in better disease control.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Carcinoma de Pulmón de Células no Pequeñas
/
Ácidos Nucleicos Libres de Células
/
Neoplasias Pulmonares
/
Células Neoplásicas Circulantes
/
Recurrencia Local de Neoplasia
Tipo de estudio:
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Future Oncol
Año:
2021
Tipo del documento:
Article
País de afiliación:
China